421 related articles for article (PubMed ID: 37282450)
1. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.
Bigi A; Cascella R; Cecchi C
Neural Regen Res; 2023 Nov; 18(11):2332-2342. PubMed ID: 37282450
[TBL] [Abstract][Full Text] [Related]
2. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
Cascella R; Bigi A; Cremades N; Cecchi C
Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy.
Bigi A; Ermini E; Chen SW; Cascella R; Cecchi C
Life (Basel); 2021 May; 11(5):. PubMed ID: 34064766
[TBL] [Abstract][Full Text] [Related]
4. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
5. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
Alam P; Bousset L; Melki R; Otzen DE
J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394
[TBL] [Abstract][Full Text] [Related]
6. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
8. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
9. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
[TBL] [Abstract][Full Text] [Related]
10. Neurons and Glia Interplay in α-Synucleinopathies.
Mavroeidi P; Xilouri M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066733
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with structurally adapted fungal protein fibrils induces immunity to Parkinson's disease.
Pesch V; Flores-Fernandez JM; Reithofer S; Ma L; Özdüzenciler P; Busch Y; Sriraman A; Wang Y; Amidian S; Kroepel CVM; Müller L; Lien Y; Rudtke O; Frieg B; Schröder GF; Wille H; Tamgüney G
Brain; 2024 May; 147(5):1644-1652. PubMed ID: 38428032
[TBL] [Abstract][Full Text] [Related]
12. The 3D structure of lipidic fibrils of α-synuclein.
Frieg B; Antonschmidt L; Dienemann C; Geraets JA; Najbauer EE; Matthes D; de Groot BL; Andreas LB; Becker S; Griesinger C; Schröder GF
Nat Commun; 2022 Nov; 13(1):6810. PubMed ID: 36357403
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Protein Aggregates Using Bimolecular Fluorescence Complementation.
Prasad V; Voigt A
Methods Mol Biol; 2019; 1873():183-193. PubMed ID: 30341610
[TBL] [Abstract][Full Text] [Related]
14. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
[TBL] [Abstract][Full Text] [Related]
15. Alpha Synuclein: Neurodegeneration and Inflammation.
Forloni G
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982988
[TBL] [Abstract][Full Text] [Related]
16. Characterization of α-synuclein oligomers formed in the presence of lipid vesicles.
Dasari AKR; Sengupta U; Viverette E; Borgnia MJ; Kayed R; Lim KH
Biochem Biophys Rep; 2024 Jul; 38():101687. PubMed ID: 38545462
[TBL] [Abstract][Full Text] [Related]
17. Phase separation and other forms of α-Synuclein self-assemblies.
Poudyal M; Sakunthala A; Mukherjee S; Gadhe L; Maji SK
Essays Biochem; 2022 Dec; 66(7):987-1000. PubMed ID: 36373662
[TBL] [Abstract][Full Text] [Related]
18. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
19. Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein.
Gibbs E; Zhao B; Roman A; Plotkin SS; Peng X; Hsueh SCC; Aina A; Wang J; Shyu C; Yip CK; Nam SE; Kaplan JM; Cashman NR
Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140270
[TBL] [Abstract][Full Text] [Related]
20. Autophagy in α-Synucleinopathies-An Overstrained System.
Fellner L; Gabassi E; Haybaeck J; Edenhofer F
Cells; 2021 Nov; 10(11):. PubMed ID: 34831366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
